博文
Cancer Cell：对接受免疫治疗的癌症患者进行错配修复测试的基准测试
||
Cancer Cell：对接受免疫治疗的癌症患者进行错配修复测试的基准测试
https://www.ebiotrade.com/newsf/2023-12/20231229033951439.htm
学
http://www.pubmedplus.cn/P/SearchQuickResult?wd=d71f4cc5-111f-4168-9454-cf5645c5c7d5
| 01. | DNA Mismatch Repair | 173 篇 | 100.000% |
| 02. | MutS Homolog 2 Protein | 173 篇 | 100.000% |
| 03. | Humans | 158 篇 | 91.329% |
| 04. | MutL Protein Homolog 1 | 116 篇 | 67.052% |
| 05. | DNA-Binding Proteins | 101 篇 | 58.382% |
| 06. | Female | 91 篇 | 52.601% |
| 07. | Adaptor Proteins, Signal Transducing | 87 篇 | 50.289% |
| 08. | Nuclear Proteins | 85 篇 | 49.133% |
| 09. | Middle Aged | 75 篇 | 43.353% |
| 10. | Male | 74 篇 | 42.775% |
https://blog.sciencenet.cn/blog-280034-1416287.html
上一篇：可编程细菌如何重塑癌症治疗
下一篇：激活骨髓细胞，对抗传统T细胞疗法的新型癌症免疫疗法
